Multi-Tissue Proteomics for Preclinical Safety: FluoSphera & Sciomics Launch Joint Service
FluoSphera and Sciomics Launch Integrated Safety and Efficacy Profiling Service for Preclinical Drug Development
One workflow, one experiment: human 3D multi-tissue biology plus high-content proteomics show not only whether a compound is efficacious or toxic, but in which tissue, through which pathway, and with which candidate biomarkers.
Geneva, Switzerland, and Neckargemünd, Germany, September 16th 2026
FluoSphera and Sciomics today launched a joint translational profiling service that combines FluoSphera’s human-relevant 3D multi-tissue platform with Sciomics’ high-content proteomic profiling. In a single experiment, pharma and biotech teams can assess efficacy, liver-dependent metabolism and organ-specific toxicity – and identify the proteins, pathways and candidate translational biomarkers behind them.
Late-stage safety failures remain one of the costliest problems in drug development. Conventional in vitro models test tissues in isolation and rely largely on terminal endpoints such as cell viability. They therefore miss organ-to-organ interactions, liver-mediated activation or inactivation, simultaneous effects on healthy and diseased tissue, and early sublethal molecular responses.
The joint offering addresses this by design rather than by adding proteomics as a downstream characterisation step: biology and protein analysis are planned together from the outset. FluoSphera brings standardized human 3D tissue models in which tumor and healthy organ tissues are exposed simultaneously under identical conditions, with liver-dependent metabolism and bioactivation built in. Sciomics profiles cellular and secreted proteins across those tissues and adds pathway analysis, biomarker discovery and translational interpretation.
“In vitro work has usually forced a choice between physiological relevance and molecular depth.
Combining human multi-tissue biology with comprehensive protein profiling removes that trade-off –
and it does so before a compound reaches costly late-stage development.”
Gregory Segala, CSO, FluoSphera
The workflow has already been successfully demonstrated in a proof-of-concept study conducted in partnership with AbbVie, with the results now being prepared for publication. The study combined human colorectal tumor spheroids, liver spheroids and human cardiac tissue in one multi-tissue system. Capecitabine was fully converted only in liver-containing conditions, allowing efficacy and toxicity responses to be linked directly to molecular changes. Proteomic profiling of lysates and secreted proteins identified distinct protein panels for tumor efficacy, cardiotoxicity and hepatotoxicity, mapping to DNA damage response, cell-cycle regulation, apoptosis and tissue-specific stress signalling – all from a single experiment.
“Developers need to know not only whether a compound triggers a biological response, but why it
occurs, how it develops, and which biomarkers predict it. Together we deliver that in one
integrated study, with richer and more actionable data than either approach alone.”
Christoph Schröder, CEO, Sciomics
The service is available immediately to biotechnology and pharmaceutical organisations seeking more predictive, mechanism-based preclinical safety and efficacy assessment. For more information about the collaboration and its applications, visit translational-safety.com.
